KR880013967A - 항비루스 화합물 - Google Patents
항비루스 화합물 Download PDFInfo
- Publication number
- KR880013967A KR880013967A KR1019880006295A KR880006295A KR880013967A KR 880013967 A KR880013967 A KR 880013967A KR 1019880006295 A KR1019880006295 A KR 1019880006295A KR 880006295 A KR880006295 A KR 880006295A KR 880013967 A KR880013967 A KR 880013967A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- amino
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 19
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- -1 methoxy, piperidino Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- UQQHOWKTDKKTHO-ICQCTTRCSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-5-(6-methoxypurin-9-yl)oxolane-3,4-diol Chemical compound C1=NC=2C(OC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O UQQHOWKTDKKTHO-ICQCTTRCSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001930 alkyl chloride group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (12)
- VZV또는 CMV 에 의해 야기되는 인체 비루스 감염의 치료또는 예방에 유용한 하기 일반식(I)의 화합물 및 이것의 약리학적 허용 유도체.상기식에서, R1은 할로겐, C1-5알콕시기; 할로겐 치환 C1-5알콕시; C1-5알킬로 단일 또는 이중치환된 아미노기, 하나이상의 불소원자로 치환된 C1-5알킬, 또는 C3-6심클로알킬, 또는 4내지 7개의 탄소원자 및 임의로 이중결합 및/ 또는 질소원자를 함유하는 고리를 갖는 아미노구성원을 나타내며; R2는 수소, 할로겐 또는 아미노를 나타낸다.
- 제 1 항에 있어서, 상기 R1은 수소이고, R2는 C1-5알콕시, C1-5알킬아미노 또는 할로겐인 것을 특징으로 하는 화합물.
- 제 1항에 있어서, 1) R2는 수소이고, R1은 메톡시, 피페리디노 또는 피롤리디노이거나 ; 또는 2)R2는 아미노이고, R1은 염소인 것을 특징으로 하는 의학치료에 유용한 식(I)의 화합물 및 이것의 약학적 허용 유도체.
- 의학적 치료에 유용한 9-β-D-아라비노푸라노실-6-메톡시-9H-푸린 또는 이것의 약학적 허용 유도체.
- VZV 또는 CMV에 의해 야기되는 인체 비루스 감염의 치료 또는 예방에 유용한 9-β-D-아라비노프라노실-6-디메틸아미노-9H-푸린 또는 이것의 약학적 허용 유도체.
- 에스테르기의 비카르보닐부분이 할로겐, C1-4알킬 또는 C1-4알콕시, 니트로 또는 아미노로 임의 치환된 직쇄 또는 측쇄 사슬, 알킬, 알콕시알킬, 아르알킬, 아릴옥시알킬, 아릴인 카르복실산 에스테르류 ; 알킬설포닐 또는 알킬아릴설포닐과같은 설포네이트 에스테르류 ; 아미노산 에스테르류 ; 및 모노-, 디-또는 트리포스페이트 에스테르류로부터 선택되는 것을 특징으로하는 식(I) (제 1항에서 정의하였음)의 화합물의 아라비노당 잔여물의 약학적 허용 에스테르류.
- 제 6 항에 있어서, 약학적 허용 에스테르는 9-β-D-아리비노푸라노실-6-메톡시-9H-푸린인 것을 특징으로 하는 약학적 허용 에스테르.
- 제 7 항에 있어서, 상기 에스테르는 9-(5-O-(4-메틸벤조일)-B-D-아라비노푸라노실)-6-메톡시-9H-푸린, 9-(5-O-(4-아미노벤조일)-B-D-하라비노푸라노실)-6-메톡시-9H-푸린 및 6-메톡시-9-(2-O-펜타노일-B-D-아라비노푸라실)-9H-푸린중에서 선택되는 것을 특징으로 하는 식(I)의 화합물의 에스테르.
- 하기 일반식 I (a)의 화합물 및 식 I (a)[여기서, R2가 염소, 불소, 수소 또는 아미노일 때, R1은 염소 또는 불소이다.]의 화합물의 2',3',5'-트리아세테이트 및 2',3',5'-트리벤질 유도체이외의 다른 약리학적 허용 유도체.상기 식에서, R1은 하롤겐, C1-5알콕시기 ; 할로겐치환 C1-5알콕기 ; C1-5알킬로 단일 또는 이중 치환된 아미노기, 하나이상의 불소 원자로 치환된 C1-5알킬, 또는 C3-6시클로알킬 또는 4 내지 7개의 탄소원자 및 임의로 이중결합 및/또는 질소원자를 함유하는 고리를 갖는 아미노 구성원을 나타내며 ; 및 R2가 수소일 때, R1은 염소, 메톡시, 메틸아미노, 에틸아미노, 디메틸아미노, 피페리디노 또는 피롤리디노를 나타내지 않고, R2가 아미노일 때, R1이 염소 또는 메틸아미노를 나타내지 않는다는 조건하에서 R2는 수소, 할로겐 또는 아미노를 나타낸다.
- 제 9 항에 있어서, 의학적 치료에 유용한 식 I (a)의 화합물 또는 이것의 약학적 허용 유도체.
- 하기의 A 또는 B반은 단계를 포함하는 것을 특징으로 하는 제 9 항의 화합물의 제조방법. A.하기 일반식(II)의 화합물을 하기 일반식(III)의 화합물과 반응시키거나 ; 또는상기 식에서, R1및 R2는 상기식에서 정의한 바와 같다.상기 식에서, X는 피리미딘 또는 푸린염기 (식(II)의 화합물이외의 것) B. 하기 일반식(IV)의 화합물을 6위치에 필요한 기를 도입할 수 있는 화합물과 반응시키고 ; 및 이후 선택적으로 또는 이와 동시에 생선된 화합물의 식 I (a)의 화합물을 이것의 약학적 허용 유도체로 전환시키거나 여기서 생성된 화합물인 약학적 허용 유도체를 별개의 약학적 허용 유도체 또는 식 I (a)의 화합물로 전환시키는 단계.상기 식에서, Z은 이탈기이며, R2는 상기식에서 정의한 바와 같다.
- 식(I) (제 1 항에서 정의하였다.)의 화합물의 활성제와 이것의 약학적 허용 담체를 포함하는 것을 특징으로 하는 약학 제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878712745A GB8712745D0 (en) | 1987-05-30 | 1987-05-30 | Antiviral compounds |
GB8712745 | 1987-05-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880013967A true KR880013967A (ko) | 1988-12-22 |
KR970009474B1 KR970009474B1 (ko) | 1997-06-13 |
Family
ID=10618179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880006295A KR970009474B1 (ko) | 1987-05-30 | 1988-05-27 | 항바이러스 화합물 |
Country Status (31)
Country | Link |
---|---|
US (2) | US5424295A (ko) |
EP (1) | EP0294114B1 (ko) |
JP (1) | JP2667873B2 (ko) |
KR (1) | KR970009474B1 (ko) |
CN (1) | CN1020107C (ko) |
AT (1) | ATE142636T1 (ko) |
AU (1) | AU622403B2 (ko) |
CA (1) | CA1330990C (ko) |
CS (1) | CS277006B6 (ko) |
CY (2) | CY2001A (ko) |
DD (2) | DD293962A5 (ko) |
DE (2) | DE122008000003I2 (ko) |
DK (1) | DK171670B1 (ko) |
ES (1) | ES2091750T3 (ko) |
FI (1) | FI89805C (ko) |
GB (1) | GB8712745D0 (ko) |
GR (1) | GR3021257T3 (ko) |
HK (1) | HK78497A (ko) |
HU (2) | HU205001B (ko) |
IL (1) | IL86531A (ko) |
LU (1) | LU91370I2 (ko) |
MC (1) | MC1935A1 (ko) |
MY (1) | MY103567A (ko) |
NL (1) | NL300302I2 (ko) |
NO (2) | NO172543C (ko) |
NZ (1) | NZ224813A (ko) |
PH (1) | PH27292A (ko) |
PL (1) | PL157684B1 (ko) |
PT (1) | PT87592B (ko) |
SA (1) | SA99200688A (ko) |
ZA (2) | ZA883829B (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8712745D0 (en) * | 1987-05-30 | 1987-07-01 | Wellcome Found | Antiviral compounds |
US6060459A (en) * | 1987-10-28 | 2000-05-09 | Pro-Neuron, Inc. | Enhancing blood cell count with oxypurine nucleosides |
DD293498A5 (de) * | 1989-07-20 | 1991-09-05 | Zi Fuer Molekularbiologie Der Adw,De | Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
KR910007655A (ko) * | 1989-10-03 | 1991-05-30 | 엠. 피. 잭슨 | 치료용 뉴클레오시드 |
US5206351A (en) * | 1990-06-15 | 1993-04-27 | Ash Stevens, Inc. | Process for the preparation of 2-amino (2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl)adenine |
GB9015914D0 (en) * | 1990-07-19 | 1990-09-05 | Wellcome Found | Heterocyclic compounds |
US5283331A (en) * | 1990-12-20 | 1994-02-01 | Nippon Kayaku Kabushiki Kaisha | 2-halogeno-oxetanocin A and phosphoric ester thereof |
GB9104165D0 (en) * | 1991-02-27 | 1991-04-17 | Wellcome Found | Novel entities for hiv therapy |
US5961987A (en) * | 1996-10-31 | 1999-10-05 | University Of Iowa Research Foundation | Ocular protein stimulants |
JP3619017B2 (ja) | 1998-06-24 | 2005-02-09 | 日本臓器製薬株式会社 | 新規アラビノシルアデニン誘導体 |
US6653318B1 (en) * | 1999-07-21 | 2003-11-25 | Yale University | 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use |
NZ520852A (en) * | 2000-02-18 | 2004-03-26 | Southern Res Inst | Intermediates and methods for synthesizing 2-chloro-9- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine |
US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
JP3421330B2 (ja) * | 2000-11-02 | 2003-06-30 | 持田製薬株式会社 | ビダラビン注射用乾燥製剤 |
EA008380B1 (ru) * | 2001-11-27 | 2007-04-27 | Анадис Фармасьютикалз, Инк. | 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ |
US7321033B2 (en) * | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
CA2499253A1 (en) * | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
ES2525567T3 (es) * | 2004-12-17 | 2014-12-26 | Anadys Pharmaceuticals, Inc. | Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos |
US20060178512A1 (en) * | 2005-02-04 | 2006-08-10 | Cheruthur Govindan | Method for preparing amino acid esters of nucleoside analogues |
AU2006318260B2 (en) | 2005-11-21 | 2012-05-17 | Anadys Pharmaceuticals, Inc. | Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one |
US7709448B2 (en) * | 2006-06-22 | 2010-05-04 | Anadys Pharmaceuticals, Inc. | Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione |
US7528115B2 (en) | 2006-07-18 | 2009-05-05 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines |
CN101092441A (zh) * | 2007-07-17 | 2007-12-26 | 北京本草天源药物研究院 | 一种奈拉滨的合成方法 |
US7846912B2 (en) * | 2007-09-13 | 2010-12-07 | Protia, Llc | Deuterium-enriched nelarabine |
CN101768197A (zh) * | 2008-12-29 | 2010-07-07 | 北京德众万全药物技术开发有限公司 | 一种奈拉滨的制备方法 |
CN103665076B (zh) * | 2012-08-30 | 2018-01-09 | 上海阳帆医药科技有限公司 | 奈拉滨的制备方法 |
CN104892709B (zh) * | 2015-06-04 | 2018-01-19 | 新乡学院 | 一种合成奈拉滨的方法 |
WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
WO2022258014A1 (zh) * | 2021-06-09 | 2022-12-15 | 正大天晴药业集团股份有限公司 | 用于制备奈拉滨的重组基因工程菌及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759011A (fr) * | 1969-11-17 | 1971-05-17 | Wellcome Found | Aminopurines |
US3758684A (en) * | 1971-09-07 | 1973-09-11 | Burroughs Wellcome Co | Treating dna virus infections with amino purine derivatives |
US4048432A (en) * | 1976-05-17 | 1977-09-13 | Parke, Davis & Company | 9-(3,5-Di-O-acyl-β-D-arabinofuranosyl)adenine compounds and method for their production |
US4055718A (en) * | 1976-05-17 | 1977-10-25 | Parke, Davis & Company | 9-(2-O-Acyl-β-D-arabinofuranosyl)-adenine compounds and method for their production |
US4055717A (en) * | 1976-05-17 | 1977-10-25 | Parke, Davis & Company | 9-(3-O-Acyl-β-D-arabinofuranosyl)adenine compounds, 9-(2,3-di-O-acyl-β-D-arabinofuranosyl)-adenine compounds, and method for their production |
JPS5515716A (en) * | 1978-07-18 | 1980-02-04 | Ajinomoto Co Inc | Production of purine arabinoside |
JPS6053941B2 (ja) * | 1977-08-10 | 1985-11-28 | 日本電気株式会社 | バイアスライト駆動方式 |
US4371613A (en) * | 1977-08-10 | 1983-02-01 | Ajinomoto Company Incorporated | Method for producing purine arabinosides |
GB1573777A (en) * | 1977-11-03 | 1980-08-28 | Wellcome Found | 9-d-arabinonucleosides and an enzymatic process for their preparation |
US4495180A (en) * | 1982-06-21 | 1985-01-22 | Merck & Co., Inc. | Prodrugs of Ara-A an antiviral agent |
JPS58225097A (ja) * | 1982-06-23 | 1983-12-27 | Yamasa Shoyu Co Ltd | ヌクレオシド5′−アルキルもしくはアルケニルりん酸 |
EP0199451B1 (en) * | 1985-03-16 | 1996-03-06 | The Wellcome Foundation Limited | Therapeutic nucleosides |
GB8712745D0 (en) * | 1987-05-30 | 1987-07-01 | Wellcome Found | Antiviral compounds |
-
1987
- 1987-05-30 GB GB878712745A patent/GB8712745D0/en active Pending
-
1988
- 1988-05-27 DE DE122008000003C patent/DE122008000003I2/de active Active
- 1988-05-27 MC MC881981A patent/MC1935A1/xx unknown
- 1988-05-27 AT AT88304813T patent/ATE142636T1/de active
- 1988-05-27 JP JP63128562A patent/JP2667873B2/ja not_active Expired - Lifetime
- 1988-05-27 MY MYPI88000569A patent/MY103567A/en unknown
- 1988-05-27 HU HU895829A patent/HU205001B/hu unknown
- 1988-05-27 IL IL86531A patent/IL86531A/xx active Protection Beyond IP Right Term
- 1988-05-27 NO NO882357A patent/NO172543C/no not_active IP Right Cessation
- 1988-05-27 CN CN88103820A patent/CN1020107C/zh not_active Expired - Lifetime
- 1988-05-27 DD DD88340139A patent/DD293962A5/de not_active IP Right Cessation
- 1988-05-27 ZA ZA883829A patent/ZA883829B/xx unknown
- 1988-05-27 DE DE3855522T patent/DE3855522T2/de not_active Expired - Lifetime
- 1988-05-27 AU AU16718/88A patent/AU622403B2/en not_active Expired
- 1988-05-27 KR KR1019880006295A patent/KR970009474B1/ko not_active IP Right Cessation
- 1988-05-27 FI FI882511A patent/FI89805C/fi not_active IP Right Cessation
- 1988-05-27 EP EP88304813A patent/EP0294114B1/en not_active Expired - Lifetime
- 1988-05-27 PT PT87592A patent/PT87592B/pt not_active IP Right Cessation
- 1988-05-27 DD DD88316143A patent/DD282694A5/de not_active IP Right Cessation
- 1988-05-27 CA CA000567966A patent/CA1330990C/en not_active Expired - Lifetime
- 1988-05-27 ES ES88304813T patent/ES2091750T3/es not_active Expired - Lifetime
- 1988-05-27 CS CS883635A patent/CS277006B6/cs not_active IP Right Cessation
- 1988-05-27 PL PL1988272729A patent/PL157684B1/pl unknown
- 1988-05-27 HU HU882706A patent/HU199870B/hu active Protection Beyond IP Right Term
- 1988-05-27 NZ NZ224813A patent/NZ224813A/en unknown
- 1988-05-27 DK DK289788A patent/DK171670B1/da not_active IP Right Cessation
-
1989
- 1989-09-01 PH PH39191A patent/PH27292A/en unknown
- 1989-10-05 ZA ZA897598A patent/ZA897598B/xx unknown
-
1993
- 1993-08-23 US US08/110,487 patent/US5424295A/en not_active Expired - Lifetime
-
1995
- 1995-03-14 US US08/403,363 patent/US5539098A/en not_active Expired - Lifetime
-
1996
- 1996-10-03 GR GR960402608T patent/GR3021257T3/el unknown
-
1997
- 1997-06-12 HK HK78497A patent/HK78497A/xx not_active IP Right Cessation
- 1997-12-05 CY CY200197A patent/CY2001A/xx unknown
-
1999
- 1999-10-18 SA SA99200688A patent/SA99200688A/ar unknown
-
2007
- 2007-10-10 LU LU91370C patent/LU91370I2/fr unknown
- 2007-11-02 NL NL300302C patent/NL300302I2/nl unknown
- 2007-12-21 NO NO2007016C patent/NO2007016I2/no unknown
-
2008
- 2008-01-25 CY CY200800001C patent/CY2008001I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880013967A (ko) | 항비루스 화합물 | |
KR950000728A (ko) | 포스포네이트 뉴클레오티드 에스테르 유도체 | |
KR890003761A (ko) | 치료학적 아시클릭 뉴클레오시드 | |
CA2190983A1 (en) | New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | |
EP0786458A3 (en) | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents | |
DK0656778T3 (da) | Enantiomert rene beta-D-dioxolannukleosider | |
DK159444C (da) | Analogifremgangsmaade til fremstilling af derivater af 9-(2-hydroxyethoxymethyl)guanin | |
HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
AU4690989A (en) | Antiviral cytosine and guanine derivatives | |
KR910015575A (ko) | 1H-이미다조[4,5-c]퀴놀린-4-아민 | |
FI875229A (fi) | Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi | |
DE68901153D1 (de) | Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
BR0011521B8 (pt) | compostos nucleósidos de purina de 4 -c-etinila | |
MY103801A (en) | Dideoxydidehydrocarbocyclic nucleosides | |
KR870006900A (ko) | 항바이러스 조성물 | |
KR910007655A (ko) | 치료용 뉴클레오시드 | |
DE69006116D1 (de) | Peptid-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
KR880012628A (ko) | 치료학적인 뉴클레오시드 | |
ATE73449T1 (de) | 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen. | |
PT96164A (pt) | Processo de preparacao de uma composicao farmaceutica a base de derivados de fluoroquinolona | |
NO852514L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido (5,4-d) pyrimidin-derivater. | |
ES2013379A6 (es) | Procedimiento para preparar 6-sulfenamido-6, sulfinamido- y 6-sulfonamido-purinas, nucleosidos de purinas y nucleotidos de purinas antitumorales. | |
KR910000728A (ko) | 시클로펜탄 유도체 | |
DE69200365D1 (de) | Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria. | |
KR950014110A (ko) | 사이클로프로판 유도체 및 이를 포함하는 항바이러스제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
G160 | Decision to publish patent application | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110929 Year of fee payment: 15 |
|
EXPY | Expiration of term |